Kite teams with GE in bid to lower T cell production costs through automation

Kite Pharma ($KITE) has teamed up with GE Global Research ($GE) to develop an automated production system for engineered T cell therapies. The development of such a system could help Kite control the cost of manufacturing its closely watched autologous immuno-oncology drugs. Dendreon, a pioneer in autologous cancer treatment, was dogged by high manufacturing costs throughout its attempt to make its cancer vaccine Provenge a success. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.